1. Binder C, Brange J 1997 Insulin chemistry and pharmacokinetics. In: Porte D, Jr., Sherwin R (eds) Ellenberg's and Rifkin's Diabetes Mellitus, 5th edition ed. Appleton and Lange, Stamford, CT, p 689
2. FDA/CDER resources page. Frequently asked questions about importing beef or pork insulin for personal use. Food and Drug Administration website. Available at: http://www.fda.gov/cder/drug/beefandporkinsulin/default.htm. Accessed September 16, 2006.
3. May 2004 Eli Lilly and Company. Humalog Package Insert.
4. March 2005 Eli Lilly and Company. Humalog Mix75/25 Package Insert.
5. February 2006 Sanofi-Aventis U.S. Lantus Package Insert.
6. October 2005 Novo Nordisk, Inc. Novolog Package Insert.
7. November 2005 Novo Nordisk Inc. Novolog Mix 70/30 Package Insert.
8. January 2006 Eli Lilly and Company. Humalog Mix50/50 Package Insert.
9. October 2005 Novo Nordisk Inc. Levemir Package Insert.
10. November 2005 Aventis Pharmaceuticals Inc. Apidra Package Insert.
11. Kurtzhals P, Schaffer L, Sorensen A, et al. 2000 Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999-1005
12. Home PD, Ashwell SG 2002 An overview of insulin glargine. Diabetes Metab Res Rev 18 Suppl 3:S57-63
13. Schernthaner G 1993 Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 16 Suppl 3:155-65
14. Burge MR, Schade DS 1997 Insulins. Endocrinol Metab Clin North Am 26:575-98
15. Carlisle BA, Koda-Kimble MA, Kroon LA 2005 Diabetes Mellitus. In: Applied Therapeutics. The Clinical Use of Drugs. Lippincott Williams & Wilkins, Baltimore, MD, pp 50-1.
16. ter Braak EW, Woodworth JR, Bianchi R, et al. 1996 Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 19:1437-40
17. Francis AJ, Hanning I, Alberti KG 1985 The influence of insulin antibody levels on the plasma profiles and action of subcutaneously injected human and bovine short acting insulins. Diabetologia 28:330-4
18. Nolte MS, Karam, J.H. 2001 Pancreatic Hormones & Antidiabetic Drugs. In: Katzung B (ed) Basic and Clinical Pharmacology, 8th ed. Lange Medical Books/McGraw Hill, New York, pp 711-734
19. Rabkin R, Ryan MP, Duckworth WC 1984 The renal metabolism of insulin. Diabetologia 27:351-7
20. Pampanelli S, Torlone E, Ialli C, et al. 1995 Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function. Diabetes Care 18:1452-9
21. Brunelle BL, Llewelyn J, Anderson JH, Jr., Gale EA, Koivisto VA 1998 Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 21:1726-31
22. Lalli C, Ciofetta M, Del Sindaco P, et al. 1999 Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 22:468-77
23. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T 1997 Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 46:440-3
24. Kaufman FR, Halvorson M, Kim C, Pitukcheewanont P 2000 Use of insulin pump therapy at nighttime only for children 7-10 years of age with type 1 diabetes. Diabetes Care 23:579-82
25. Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R 1999 Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care 22:784-8
26. Kumar D 1997 Lispro analog for treatment of generalized allergy to human insulin. Diabetes Care 20:1357-9
27. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L 2000 Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 23:583-8
28. Bode BW, Strange P 2001 Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care 24:69-72
29. Bolli GB, Owens DR 2000 Insulin glargine. Lancet 356:443-5
30. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T 2000 Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23:644-9
31. Mudaliar S, Mohideen P, Deutsch R, et al. 2002 Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles. Diabetes Care 25:1597-602
32. Yki-Jarvinen H, Dressler A, Ziemen M 2000 Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 23:1130-6
33. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA 2000 Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 23:639-43
34. DeWitt DE, Dugdale DC 2003 Using new insulin strategies in the outpatient treatment of diabetes: clinical applications. Jama 289:2265-9
35. 1993 The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-86
36. 1998 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-53
37. ADA 2004 American Diabetes Association Position Statement. Insulin administration. Diabetes Care 27 Suppl 1:S106-109
38. Peters AL, Davidson MB 1987 Effect of storage on action of NPH and regular insulin mixtures. Diabetes Care 10:799-800
39. Roach P, Woodworth JR 2002 Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Clin Pharmacokinet 41:1043-57
40. Joseph SE, Korzon-Burakowska A, Woodworth JR, et al. 1998 The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. Diabetes Care 21:2098-102
41. Bell DS, Clements RS, Jr., Perentesis G, Roddam R, Wagenknecht L 1991 Dosage accuracy of self-mixed vs premixed insulin. Arch Intern Med 151:2265-9
42. Hirsch IB 1999 Type 1 diabetes mellitus and the use of flexible insulin regimens. Am Fam Physician 60:2343-52, 2355-6
43. ADA 1998 Medical Management of Insulin-Dependent (Type I) Diabetes Mellitus, 3rd edition ed. American Diabetes Association, Alexandria, VA
44. 2002 Practical insulin: A handbook for prescribing providers. American Diabetes Association, Alexandria, VA
45. Turner RC, Cull CA, Frighi V, Holman RR 1999 Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. Jama 281:2005-12
46. Hermann LS 2000 Optimising therapy for insulin-treated type 2 diabetes mellitus. Drugs Aging 17:283-94
47. Yki-Jarvinen H 2001 Combination therapies with insulin in type 2 diabetes. Diabetes Care 24:758-67
48. ADA 2006 Standards of medical care in diabetes--2006. Diabetes Care 29 Suppl 1:S4-42
49. Chantelau E, Kohner EM 1997 Why some cases of retinopathy worsen when diabetic control improves. Bmj 315:1105-6
50. Fanelli CG, Pampanelli S, Porcellati F, Rossetti P, Brunetti P, Bolli GB 2002 Administration of neutral protamine Hagedorn insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial. Ann Intern Med 136:504-14
51. Francis AJ, Home PD, Hanning I, Alberti KG, Tunbridge WM 1983 Intermediate acting insulin given at bedtime: effect on blood glucose concentrations before and after breakfast. Br Med J (Clin Res Ed) 286:1173-6
52. Raskin P, Bode BW, Marks JB, et al. 2003 Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care 26:2598-603
53. Mudaliar S, Edelman SV 2001 Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am 30:935-82
54. Bode BW, Sabbah HT, Gross TM, Fredrickson LP, Davidson PC 2002 Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev 18 Suppl 1:S14-20
55. Bode BW, Tamborlane WV, Davidson PC 2002 Insulin pump therapy in the 21st century. Strategies for successful use in adults, adolescents, and children with diabetes. Postgrad Med 111:69-77; quiz 27
56. Pickup J, Keen H 2002 Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 25:593-8
57. Riddle MC, Rosenstock J, Gerich J 2003 The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26:3080-6
58. Holleman F, van den Brand JJ, Hoven RA, et al. 1996 Comparison of LysB28, ProB29-human insulin analog and regular human insulin in the correction of incidental hyperglycemia. Diabetes Care 19:1426-9
59. DeWitt DE, Hirsch IB 2003 Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. Jama 289:2254-64
60. Kong N, Kitchen MM, Ryder RE 2000 The use of lispro for high sugar content snacks between meals in intensive insulin regimens. Diabet Med 17:331-2
61. 2002 Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. Bmj 325:746
62. Stahl M, Brandslund I, Jorgensen LG, Hyltoft Petersen P, Borch-Johnsen K, de Fine Olivarius N 2002 Can capillary whole blood glucose and venous plasma glucose measurements be used interchangeably in diagnosis of diabetes mellitus? Scand J Clin Lab Invest 62:159-66
63. Rave K, et al. 2005 Time-action profile of inhaled
insulin in comparison with subcutaneously injected insulin lispro and regular
human insulin.
64. Plank J, et al. 2005. A double-blind,
randomized, dose-response study investigating the pharmacodynamic and
pharmacokinetic properties of the long-acting insulin analog detemir.
65. Lepore M, et al. 2000. Pharmacokinetics
and pharmacodynamics of subcutaneous injection of long-acting human insulin
analog glargine, NPH insulin, and ultralente human insulin and continuous
subcutaneous infusion of insulin lispro.
66. Meneghini
LF, Rosenberg KH, Koenen C, Merilainen MJ, Lüddeke HJ. 2007. Insulin
detemir improves glycaemic control with less hypoglycaemia and no weight gain
in patients with type 2 diabetes who were insulin naive or treated with NPH or
insulin glargine: clinical practice experience from a German subgroup of the
PREDICTIVE study*
67. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. 2008. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 51(3): 408–416.